Publicacions en col·laboració amb investigadors/es de Centro Nacional de Investigaciones Cardiovasculares Carlos III (6)

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

2021

  1. HAP-Multitag, a PET and Positive MRI Contrast Nanotracer for the Longitudinal Characterization of Vascular Calcifications in Atherosclerosis

    ACS Applied Materials and Interfaces, Vol. 13, Núm. 38, pp. 45279-45290

2019

  1. Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model

    Journal of the American College of Cardiology, Vol. 74, Núm. 15, pp. 1910-1923

2017

  1. Iron oxide nanoparticle-based MRI contrast agents: Characterization and in vivo use

    Magnetic Characterization Techniques for Nanomaterials (Springer Berlin Heidelberg), pp. 85-120

2012

  1. Apparent diffusion coefficient of hyperpolarized 3He with minimal influence of the residual gas in small animals

    NMR in Biomedicine, Vol. 25, Núm. 9, pp. 1026-1032